New England Journal of Medicine: Retatrutide Phase 2 trial results - The landmark study establishing retatrutide efficacy and safety across multiple dose groups New England Journal of Medicine: STEP 1 semaglutide trial results - The pivotal trial demonstrating semaglutide 2.4 mg weight loss efficacy ClinicalTrials.gov: Retatrutide TRIUMPH program - Current status and details of all ongoing Phase 3 retatrutide trials FDA prescribing information for Wegovy (semaglutide 2.4 mg) - Complete approved labeling including dosing, safety, and clinical data New England Journal of Medicine: SELECT cardiovascular outcomes trial - The trial demonstrating semaglutide 20% reduction in major cardiovascular events These primary sources should be the foundation for any serious evaluation of either compound
To manage nausea, start with a lower dose and gradually increase it as your body gets used to the medication
[1] GLP-1s have revolutionized weight loss but the sticker shock is real, especially if insurance wont help
Additionally, if you increased physical activity but did not see lasting weight loss, note that as well
If Im already providing comprehensive care for a patients mental health and I understand their metabolic issues, it may make more sense for me to prescribe and monitor the GLP-1 rather than sending them to yet another provider who wont address the integrated picture
Brubaker completed both her undergrad and PhD at McGill University.